Novo Nordisk A/S NONOF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 12.21B | 15.16B | 12.34B | 11.74B | 11.69B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.21B | 15.16B | 12.34B | 11.74B | 11.69B |
| Cost of Revenue | 2.66B | 2.13B | 2.21B | 2.27B | 1.95B |
| Gross Profit | 9.55B | 13.03B | 10.13B | 9.48B | 9.74B |
| SG&A Expenses | 2.54B | 2.07B | 2.67B | 2.47B | 2.87B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 36.42M | 16.60M | -12.63M | -- | 3.50M |
| Total Operating Expenses | 7.02B | 5.83B | 6.84B | 6.54B | 6.60B |
| Operating Income | 5.20B | 9.34B | 5.49B | 5.21B | 5.09B |
| Income Before Tax | 4.18B | 9.74B | 5.33B | 4.00B | 5.14B |
| Income Tax Expenses | 916.02M | 2.13B | 1.14B | 863.28M | 1.11B |
| Earnings from Continuing Operations | 3.27B | 7.60B | 4.19B | 3.13B | 4.03B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.27B | 7.60B | 4.19B | 3.13B | 4.03B |
| EBIT | 5.20B | 9.34B | 5.49B | 5.21B | 5.09B |
| EBITDA | 5.76B | 9.89B | 5.71B | 5.72B | 5.66B |
| EPS Basic | 0.74 | 1.71 | 0.94 | 0.71 | 0.91 |
| Normalized Basic EPS | 0.73 | 1.37 | 0.82 | 0.77 | 0.72 |
| EPS Diluted | 0.74 | 1.71 | 0.94 | 0.70 | 0.91 |
| Normalized Diluted EPS | 0.73 | 1.37 | 0.82 | 0.77 | 0.72 |
| Average Basic Shares Outstanding | 4.43B | 4.44B | 4.44B | 4.44B | 4.45B |
| Average Diluted Shares Outstanding | 4.44B | 4.45B | 4.45B | 4.45B | 4.45B |
| Dividend Per Share | 0.58 | -- | 1.24 | 0.00 | 0.57 |
| Payout Ratio | 0.00% | 72.72% | 0.00% | 83.29% | -- |